The estimated Net Worth of Thomas Mcgauley is at least $27.4 Thousand dollars as of 23 May 2012. Thomas Mcgauley owns over 10,000 units of Galectin Therapeutics Inc stock worth over $27,400 and over the last 12 years Thomas sold GALT stock worth over $0.
Thomas has made over 1 trades of the Galectin Therapeutics Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Thomas bought 10,000 units of GALT stock worth $23,500 on 23 May 2012.
The largest trade Thomas's ever made was buying 10,000 units of Galectin Therapeutics Inc stock on 23 May 2012 worth over $23,500. On average, Thomas trades about 5,000 units every 0 days since 2012. As of 23 May 2012 Thomas still owns at least 10,000 units of Galectin Therapeutics Inc stock.
You can see the complete history of Thomas Mcgauley stock trades at the bottom of the page.
Thomas's mailing address filed with the SEC is C/O GALECTIN THERAPUTICS INC., 7 WELLS AVENUE, SUITE 34, NEWTON, MA, 02459.
Over the last 13 years, insiders at Galectin Therapeutics Inc have traded over $21,823,082 worth of Galectin Therapeutics Inc stock and bought 5,077,107 units worth $21,362,250 . The most active insiders traders include Richard E Uihlein, James C Czirr, and Fund, L.P.10 X Capital Mana.... On average, Galectin Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $226,012. The most recent stock trade was executed by Richard A. Jr. Zordani on 22 August 2024, trading 3,500 units of GALT stock currently worth $8,050.
galectin therapeutics (nasdaq: galt) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. drug candidates based on the company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function. we use naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. using these unique carbohydrate-based candidate compounds that bind and inhibit galectin proteins, we are pursuing therapies for indications where galectins have a demonstrated role in the pathogenesis of a particular disease. we focus on diseases with serious, life threatening consequences to patients, and those where current treatment options are limited. our strategy is to establish clinical development approaches that add value to the company in the shortest time possible, and to seek partners as the program advances and requires much
Galectin Therapeutics Inc executives and other stock owners filed with the SEC include: